相关实验视频

Updated: Apr 30, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

基于药物敏感性相关基因的风险评分模型有可能预测口腔状细胞癌的预后

Yao Ma, Yunpeng Li, Sasa Ding

Oral health & preventive dentistry

|August 5, 2025

概括

这项研究开发了一种新的风险评分模型,使用四种药物敏感性基因来预测口腔状细胞癌 (OSCC) 患者的预后. 该模型有助于个性化治疗策略和免疫治疗决策.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
生物信息学是一种生物信息学.

背景情况:

口腔状细胞癌 (OSCC) 是一种常见的癌症,患者的结局不同.
预测性生物标志物对于OSCC的个性化治疗策略至关重要.

研究的目的:

为OSCC患者开发和验证预后风险评分模型.
确定与OSCC预后相关的关键药物敏感性相关基因.
探索风险得分,瘤微环境和潜在的免疫治疗点之间的关系.

主要方法:

利用了来自TCGA和ICGC数据库的转录组数据,用于OSCC患者.
进行了差异基因表达分析,LASSO-Cox回归和Kaplan-Meier生存分析.
进行基因组丰富分析 (GSEA),免疫透分析,并构建了一个名ogram模型.

主要成果:

确定了四个预后基因 (IGF2BP2,PLAU,CEP55,CMYA5) 并开发了一个预测风险评分模型.
该模型的预后值独立于临床因素,并且在名图中与年龄相结合时改善了个性化预测.
在高风险和低风险组之间观察到不同的免疫透模式和TP53突变率,这表明免疫治疗的含义.

结论:

基于IGF2BP2,PLAU,CEP55和CMYA5开发的风险评分模型有效预测OSCC患者的预后.
该模型为个性化风险分层和指导OSCC治疗决策提供了一个潜在的工具.
研究结果强调了瘤微环境和特定基因在OSCC进展和治疗反应中的作用.

关键词:

CEP55 CEP55 的使用情况.在CMYA5中,CMYA5是指CMYA5.在IGF2BP2BP2的基础上.这是OSCCCC的OSCC.在 PLAU PLAUU 中.预后预后预后风险评分风险评分是什么意思

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

Published on: November 2, 2020

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...